Aa
baraclude too expensive!
Hello everyone! My doctor have given me prescription for baraclude and even with my insurance I wluld still have to pay a lot! I am very stressed out about not being able to pay for. As an alternative, I am considering ordering them from canada online websites. Has anybody ordered any kind of prescriptions thru canada? If so, is it legit?? Please shed some light. Thank you.
H
H
Have you tried BARACLUDE ALL IN ONE access program, you can get upto $200 assistance in your co pay from BMS. Call their 800 number mentioned below-
http://www.baraclude.com/index.aspx
http://www.baraclude.com/index.aspx
whoops...its in the article "Baraclude brought in $241 million in the U.S. last year, and it's expected to generate $260 million for 2013."
My father has filled his prescriptions through the Canadian pharmacies online before. Heres a ratings list:
http://www.pharmacychecker.com/onlinepharmacyratings.asp
My father has filled his prescriptions through the Canadian pharmacies online before. Heres a ratings list:
http://www.pharmacychecker.com/onlinepharmacyratings.asp
You sure its even still available?
February 12, 2013
A U.S. court has struck Baraclude from the patent list. The Bristol-Myers Squibb ($BMY) hepatitis B drug saw its composition of matter patent invalidated in a court fight with Teva Pharmaceutical Industries ($TEVA), which wants to sell its own version. The patent had been due to expire in 2015.
It's unclear whether the ruling will expose Baraclude to immediate generic competition. Teva hasn't yet won the FDA's blessing for its copy; as soon as it asked the FDA for approval, Bristol-Myers sued, triggering a 30-month waiting period under the Hatch-Waxman Act. Sandoz, the Novartis ($NVS) generics unit, also has an FDA app pending--and has been fighting its own patent-challenge case since last June.
Baraclude brought in $241 million in the U.S. last year, and it's expected to generate $260 million for 2013. That's a small fraction of Baraclude's worldwide sales of $1.4 billion last year, and ISI Group analyst Mark Schoenebaum figures that a Teva knock-off in the U.S. wouldn't damage sales enough to dent Bristol-Myers' 2013 profits forecast, Forbes reports.
http://www.fiercepharma.com/story/bristol-myers-loses-baraclude-patent-fight-teva/2013-02-12
February 12, 2013
A U.S. court has struck Baraclude from the patent list. The Bristol-Myers Squibb ($BMY) hepatitis B drug saw its composition of matter patent invalidated in a court fight with Teva Pharmaceutical Industries ($TEVA), which wants to sell its own version. The patent had been due to expire in 2015.
It's unclear whether the ruling will expose Baraclude to immediate generic competition. Teva hasn't yet won the FDA's blessing for its copy; as soon as it asked the FDA for approval, Bristol-Myers sued, triggering a 30-month waiting period under the Hatch-Waxman Act. Sandoz, the Novartis ($NVS) generics unit, also has an FDA app pending--and has been fighting its own patent-challenge case since last June.
Baraclude brought in $241 million in the U.S. last year, and it's expected to generate $260 million for 2013. That's a small fraction of Baraclude's worldwide sales of $1.4 billion last year, and ISI Group analyst Mark Schoenebaum figures that a Teva knock-off in the U.S. wouldn't damage sales enough to dent Bristol-Myers' 2013 profits forecast, Forbes reports.
http://www.fiercepharma.com/story/bristol-myers-loses-baraclude-patent-fight-teva/2013-02-12
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
